Long Island University professors have published a groundbreaking study in Nature Journal Scientific Reports that serves to advance the treatment of cirrhosis, a liver disease that kills over 1.3 million people per year. Dr. Jeffrey Idle, director and endowed professor of Arthur G. Zupko’s Institute for Systems Pharmacology and Pharmacogenomics, and Dr. Diren Beyoglu, associate director and associate professor of Arthur G. Zupko’s Institute for Systems Pharmacology and Pharmacogenomics, found that fetal bile acids, normally absent in adults, reach increasingly high levels in plasma as liver cirrhosis progresses, adding an important biomarker for evaluating the stages of cirrhosis.
